• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞色素与两种抗结核候选药物 Q203 和 TB47 形成的复合物结构。

Structure of cytochrome in complex with Q203 and TB47, two anti-TB drug candidates.

机构信息

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, China.

State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin, China.

出版信息

Elife. 2021 Nov 25;10:e69418. doi: 10.7554/eLife.69418.

DOI:10.7554/eLife.69418
PMID:34819223
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8616580/
Abstract

Pathogenic mycobacteria pose a sustained threat to global human health. Recently, cytochrome complexes have gained interest as targets for antibiotic drug development. However, there is currently no structural information for the cytochrome complex from these pathogenic mycobacteria. Here, we report the structures of cytochrome alone (2.68 Å resolution) and in complex with clinical drug candidates Q203 (2.67 Å resolution) and TB47 (2.93 Å resolution) determined by single-particle cryo-electron microscopy. cytochrome forms a dimeric assembly with endogenous menaquinone/menaquinol bound at the quinone/quinol-binding pockets. We observe Q203 and TB47 bound at the quinol-binding site and stabilized by hydrogen bonds with the side chains of Thr and Glu, residues that are conserved across pathogenic mycobacteria. These high-resolution images provide a basis for the design of new mycobacterial cytochrome inhibitors that could be developed into broad-spectrum drugs to treat mycobacterial infections.

摘要

致病分枝杆菌对全球人类健康构成持续威胁。最近,细胞色素 c 复合物作为抗生素药物开发的靶点引起了关注。然而,目前尚无这些致病分枝杆菌的细胞色素 c 复合物的结构信息。在这里,我们通过单颗粒冷冻电子显微镜报告了细胞色素 c 单独(2.68 Å 分辨率)和与临床药物候选物 Q203(2.67 Å 分辨率)和 TB47(2.93 Å 分辨率)复合物的结构。细胞色素 c 形成二聚体组装,内源性menaquinone/menaquinol 结合在醌/氢醌结合口袋中。我们观察到 Q203 和 TB47 结合在氢醌结合位点,并通过与 Thr 和 Glu 侧链的氢键稳定,这些残基在致病分枝杆菌中是保守的。这些高分辨率图像为设计新的分枝杆菌细胞色素 c 抑制剂提供了基础,这些抑制剂可以开发成广谱药物来治疗分枝杆菌感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/cd6660ea426a/elife-69418-fig7-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/ab57a7fe86e0/elife-69418-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/9a5250e271f3/elife-69418-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/4777aa934e90/elife-69418-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/c4459c38c0dd/elife-69418-fig2-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/9c6a05327a8e/elife-69418-fig2-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/93e8e337263b/elife-69418-fig2-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/d95dc825cd2b/elife-69418-fig2-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/d069490f7173/elife-69418-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/64c67d668ee8/elife-69418-fig3-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/f02cf03261ec/elife-69418-fig3-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/fbe4d3bf5521/elife-69418-fig3-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/a69bc8f2dedc/elife-69418-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/1197014e1966/elife-69418-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/9dfd211acc6e/elife-69418-fig4-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/413cd0ed42e7/elife-69418-fig4-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/be8fb7c66051/elife-69418-fig4-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/587f477ceb08/elife-69418-fig4-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/58d423798d8f/elife-69418-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/ec772f2fceb1/elife-69418-fig5-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/f050dc441e56/elife-69418-fig5-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/452d6c67009b/elife-69418-fig5-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/9b0bbd2cc767/elife-69418-fig5-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/c6a893ac9878/elife-69418-fig5-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/88a4cfe8aa11/elife-69418-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/b56cfb445185/elife-69418-fig6-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/55524de1b068/elife-69418-fig6-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/a412945c814f/elife-69418-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/a0896700242d/elife-69418-fig7-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/cd6660ea426a/elife-69418-fig7-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/ab57a7fe86e0/elife-69418-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/9a5250e271f3/elife-69418-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/4777aa934e90/elife-69418-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/c4459c38c0dd/elife-69418-fig2-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/9c6a05327a8e/elife-69418-fig2-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/93e8e337263b/elife-69418-fig2-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/d95dc825cd2b/elife-69418-fig2-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/d069490f7173/elife-69418-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/64c67d668ee8/elife-69418-fig3-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/f02cf03261ec/elife-69418-fig3-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/fbe4d3bf5521/elife-69418-fig3-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/a69bc8f2dedc/elife-69418-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/1197014e1966/elife-69418-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/9dfd211acc6e/elife-69418-fig4-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/413cd0ed42e7/elife-69418-fig4-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/be8fb7c66051/elife-69418-fig4-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/587f477ceb08/elife-69418-fig4-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/58d423798d8f/elife-69418-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/ec772f2fceb1/elife-69418-fig5-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/f050dc441e56/elife-69418-fig5-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/452d6c67009b/elife-69418-fig5-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/9b0bbd2cc767/elife-69418-fig5-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/c6a893ac9878/elife-69418-fig5-figsupp5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/88a4cfe8aa11/elife-69418-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/b56cfb445185/elife-69418-fig6-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/55524de1b068/elife-69418-fig6-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/a412945c814f/elife-69418-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/a0896700242d/elife-69418-fig7-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50ea/8616580/cd6660ea426a/elife-69418-fig7-figsupp2.jpg

相似文献

1
Structure of cytochrome in complex with Q203 and TB47, two anti-TB drug candidates.细胞色素与两种抗结核候选药物 Q203 和 TB47 形成的复合物结构。
Elife. 2021 Nov 25;10:e69418. doi: 10.7554/eLife.69418.
2
The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd.细胞色素 bcc 抑制剂 Q203 的抗分枝杆菌活性可以通过细胞色素 bd 的小分子抑制来增强。
Sci Rep. 2018 Feb 8;8(1):2625. doi: 10.1038/s41598-018-20989-8.
3
Structure of mycobacterial CIIICIV respiratory supercomplex bound to the tuberculosis drug candidate telacebec (Q203).分枝杆菌 CIIICIV 呼吸超级复合物与结核候选药物特拉塞韦(Q203)结合的结构。
Elife. 2021 Sep 30;10:e71959. doi: 10.7554/eLife.71959.
4
Response of to the Cytochrome Inhibitor Q203.对细胞色素抑制剂Q203的反应。
Int J Mol Sci. 2022 Sep 7;23(18):10331. doi: 10.3390/ijms231810331.
5
The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus.QcrB 抑制剂 TB47 和 Telacebec 不会增强分枝杆菌中氯法齐明的活性。
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0096421. doi: 10.1128/AAC.00964-21. Epub 2021 Sep 20.
6
Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis.外排作用减弱了Q203对结核分枝杆菌的抗菌活性。
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.02637-16. Print 2017 Jul.
7
Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?特拉克塞巴(Q203):是否有新型有效且安全的抗结核药物即将问世?
Ceska Slov Farm. 2021 Winter;70(5):164-171. doi: 10.5817/CSF2021-5-164.
8
Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis.用于治疗耐药结核病的呼吸细胞色素bcc复合物的吡唑并[1,5-a]吡啶抑制剂
ACS Infect Dis. 2019 Feb 8;5(2):239-249. doi: 10.1021/acsinfecdis.8b00225. Epub 2018 Dec 11.
9
Carbon metabolism modulates the efficacy of drugs targeting the cytochrome bc:aa in Mycobacterium tuberculosis.碳代谢调节针对结核分枝杆菌细胞色素 bc:aa 的药物的疗效。
Sci Rep. 2019 Jun 13;9(1):8608. doi: 10.1038/s41598-019-44887-9.
10
Isolation and Characterization of a Hybrid Respiratory Supercomplex Consisting of Mycobacterium tuberculosis Cytochrome bcc and Mycobacterium smegmatis Cytochrome aa3.由结核分枝杆菌细胞色素bcc和耻垢分枝杆菌细胞色素aa3组成的混合呼吸超复合物的分离与鉴定
J Biol Chem. 2015 Jun 5;290(23):14350-60. doi: 10.1074/jbc.M114.624312. Epub 2015 Apr 10.

引用本文的文献

1
Structural and mechanistic study of a novel inhibitor analogue of cytochrome bc:aa.细胞色素bc:aa新型抑制剂类似物的结构与机制研究
NPJ Drug Discov. 2025;2(1):6. doi: 10.1038/s44386-025-00008-3. Epub 2025 Apr 2.
2
A quantitative analysis of ligand binding at the protein-lipid bilayer interface.蛋白质-脂质双层界面处配体结合的定量分析。
Commun Chem. 2025 Mar 22;8(1):89. doi: 10.1038/s42004-025-01472-8.
3
Cryo-EM of native membranes reveals an intimate connection between the Krebs cycle and aerobic respiration in mycobacteria.

本文引用的文献

1
Crystallographic investigation of the ubiquinone binding site of respiratory Complex II and its inhibitors.晶体学研究呼吸复合物 II 的泛醌结合位点及其抑制剂。
Biochim Biophys Acta Proteins Proteom. 2021 Sep;1869(9):140679. doi: 10.1016/j.bbapap.2021.140679. Epub 2021 Jun 3.
2
CHARMM-GUI supports the Amber force fields.CHARMM-GUI 支持 Amber 力场。
J Chem Phys. 2020 Jul 21;153(3):035103. doi: 10.1063/5.0012280.
3
Telacebec (Q203), a New Antituberculosis Agent.替拉塞贝克(Q203),一种新型抗结核药物。
天然膜的冷冻电镜技术揭示了分枝杆菌中三羧酸循环与有氧呼吸之间的紧密联系。
Proc Natl Acad Sci U S A. 2025 Feb 25;122(8):e2423761122. doi: 10.1073/pnas.2423761122. Epub 2025 Feb 19.
4
Exploring the Chemical Space of Mycobacterial Oxidative Phosphorylation Inhibitors Using Molecular Modeling.运用分子建模技术探索分枝杆菌氧化磷酸化抑制剂的化学空间。
ChemMedChem. 2024 Nov 18;19(22):e202400303. doi: 10.1002/cmdc.202400303. Epub 2024 Sep 20.
5
Antibiotics Trigger Host Innate Immune Response via Microbiota-Brain Communication in .抗生素通过微生物群-大脑通讯触发宿主固有免疫反应。
Int J Mol Sci. 2024 Aug 14;25(16):8866. doi: 10.3390/ijms25168866.
6
Rel-dependent decrease in the expression of ribosomal protein genes by inhibition of the respiratory electron transport chain in .Rel通过抑制呼吸电子传递链导致核糖体蛋白基因表达下降 。 (注:原英文文本表述不太完整,翻译可能会稍显生硬,但尽量忠实原文进行了翻译)
Front Microbiol. 2024 Aug 12;15:1448277. doi: 10.3389/fmicb.2024.1448277. eCollection 2024.
7
A Review of Antibacterial Candidates with New Modes of Action.具有新型作用机制的抗菌候选药物综述。
ACS Infect Dis. 2024 Oct 11;10(10):3440-3474. doi: 10.1021/acsinfecdis.4c00218. Epub 2024 Jul 17.
8
Inhibition of M. tuberculosis and human ATP synthase by BDQ and TBAJ-587.BDQ 和 TBAJ-587 对结核分枝杆菌和人 ATP 合酶的抑制作用。
Nature. 2024 Jul;631(8020):409-414. doi: 10.1038/s41586-024-07605-8. Epub 2024 Jul 3.
9
Long-range charge transfer mechanism of the IIIIV mycobacterial supercomplex.III-IV 型分枝杆菌超级复合物的长程电荷转移机制。
Nat Commun. 2024 Jun 20;15(1):5276. doi: 10.1038/s41467-024-49628-9.
10
Telacebec Interferes with Virulence Lipid Biosynthesis Protein Expression and Sensitizes to Other Antibiotics.替拉塞贝克干扰毒力脂质生物合成蛋白表达并增强对其他抗生素的敏感性。
Microorganisms. 2023 Sep 30;11(10):2469. doi: 10.3390/microorganisms11102469.
N Engl J Med. 2020 Mar 26;382(13):1280-1281. doi: 10.1056/NEJMc1913327.
4
Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus.非结核分枝杆菌与脓肿分枝杆菌的崛起。
Nat Rev Microbiol. 2020 Jul;18(7):392-407. doi: 10.1038/s41579-020-0331-1. Epub 2020 Feb 21.
5
Targeting the cytochrome oxidases for drug development in mycobacteria.针对分枝杆菌细胞色素氧化酶的药物研发。
Prog Biophys Mol Biol. 2020 May;152:45-54. doi: 10.1016/j.pbiomolbio.2020.02.001. Epub 2020 Feb 18.
6
New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis.新型 2-乙基硫代-4-甲氨基喹唑啉衍生物抑制结核分枝杆菌细胞色素 bc1 的两个亚基。
PLoS Pathog. 2020 Jan 23;16(1):e1008270. doi: 10.1371/journal.ppat.1008270. eCollection 2020 Jan.
7
Targeting the menaquinol binding loop of mycobacterial cytochrome bd oxidase.靶向分枝杆菌细胞色素 bd 氧化酶的menaquinol 结合环。
Mol Divers. 2021 Feb;25(1):517-524. doi: 10.1007/s11030-020-10034-0. Epub 2020 Jan 14.
8
Two for the price of one: Attacking the energetic-metabolic hub of mycobacteria to produce new chemotherapeutic agents.一箭双雕:靶向分枝杆菌的能量-代谢枢纽以开发新型化疗药物。
Prog Biophys Mol Biol. 2020 May;152:35-44. doi: 10.1016/j.pbiomolbio.2019.11.003. Epub 2019 Nov 13.
9
ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum Mechanics Energy Surfaces in Solution.ff19SB:针对溶液中量子力学能量面进行训练的氨基酸特异性蛋白质骨架参数。
J Chem Theory Comput. 2020 Jan 14;16(1):528-552. doi: 10.1021/acs.jctc.9b00591. Epub 2019 Dec 3.
10
Active site rearrangement and structural divergence in prokaryotic respiratory oxidases.原核生物呼吸氧化酶的活性部位重排和结构分化。
Science. 2019 Oct 4;366(6461):100-104. doi: 10.1126/science.aay0967.